Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
CSL's cash receipts from operating activities for the
six
months ended in Dec. 2025 was $1,605 Mil.
2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.
CSL's cash payments for the
six
months ended in Dec. 2025 was $0 Mil.
3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.
CSL's cash payments for the
six
months ended in Dec. 2025 was $0 Mil.
4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.
CSL's cash payments for the
six
months ended in Dec. 2025 was $0 Mil.
5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.
CSL's cash payments for the
six
months ended in Dec. 2025 was $-199 Mil.
6. Interest Received:
It represents interest received by the company in the direct cash flow method.
CSL's cash payments for the
six
months ended in Dec. 2025 was $197 Mil.
7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.
CSL's cash payments for the
six
months ended in Dec. 2025 was $-301 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).
CSL's cash flow from others for the
six
months ended in Dec. 2025 was $0 Mil.
CSL Cash Flow from Operations Related Terms
CSL Cash Flow from Operations Historical Data
* Premium members only.
The historical data trend for CSL's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
CSL's Cash Flow from Operations for the fiscal year that ended in Jun. 2025 is calculated as:
Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1,302 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Operations of $1,302 Mil mean?
CSL (CSLLY) has a Cash Flow from Operations of $1,302 Mil as of Dec. 2025. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for CSL and its competitors.
Is CSL's Cash Flow from Operations too high?
CSL's current Cash Flow from Operations is $1,302 Mil. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Cash Flow from Operations compare to VRTX and REGN?
CSL's Cash Flow from Operations of $1,302 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Biotechnology company?
A good Cash Flow from Operations depends on the Biotechnology industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for CSL and its competitors. CSL's current Cash Flow from Operations is $1,302 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.59, compared to a current price of $21.61 — trading 57.3% below its estimated fair value. The current Cash Flow from Operations is $1,302 Mil. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For CSL (CSLLY), the current Cash Flow from Operations is $1,302 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $21.61 is trading 57.3% below its estimated GF Value™ of $50.59.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Cash Flow from Operations: $1,302 Mil
GF Value™: $50.59 vs. price of $21.61 (57.3% below fair value)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
